Physician profile
Patrick L Murphy
NPI 1649279415
$1,522.85
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $260 · 2021: $289 · 2022: $218.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $218.02 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $195.14 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.30 | 2019-2022 | |
| Abbvie INC. | $129.74 | 2021-2022 | |
| Pfizer INC. | $92.77 | 2019-2022 | |
| Lilly USA, LLC | $92.43 | 2019-2021 | |
| Amgen INC. | $87.00 | 2019-2021 | |
| Amarin Pharma, INC. | $84.18 | 2019-2021 | |
| Genentech USA, INC. | $69.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $53.88 | 2019-2022 | |
| Novo Nordisk INC | $51.52 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.25 | 2019 | |
| Antares Pharma, INC. | $29.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $26.82 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.38 | 2019 | |
| Allergan, INC. | $22.93 | 2019-2020 | |
| Boston Scientific Corporation | $21.68 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.09 | 2021 | |
| Insulet Corporation | $14.61 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.61 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.58 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.90 | 2022 | |
| Horizon Therapeutics Plc | $11.74 | 2019 | |
| Shire North American Group INC | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.